In at 9:35 AM. Out by 10.

The IPO Window Is Open. Now the Fed May Slam It.

Hey there, bargain hunter. The biotech IPO machine filed another ticket on Friday, and the timing is almost aggressively inconvenient.

Scoreboard

Electra Therapeutics applied to list its common stock on the Nasdaq Global Select Market under the symbol ETRA. Jefferies, TD Cowen, Evercore ISI, and Cantor are serving as underwriters. The company did not disclose the number of shares it plans to offer or the expected price range, so the book-building process is in its earliest stage. While the S-1 landed on SEC EDGAR, odds that the Federal Reserve will keep rates steady at its September meeting declined after Fed Chair Kevin Warsh’s keynote speech at Jackson Hole, and futures pricing tracked by CME FedWatch now treats a September rate hike as roughly a coin flip.

What Electra Actually Does

Ipsoprubart is a first-in-class monoclonal antibody targeting signal regulatory proteins on immune cells, designed to selectively deplete pathological T cells and myeloid cells. The lead indication is secondary hemophagocytic lymphohistiocytosis, abbreviated sHLH. The severe hyperinflammatory syndrome has no broadly approved therapies and poor survival rates. Ipsoprubart received Breakthrough Therapy designation from the FDA and Priority Medicines designation from the European Medicines Agency for sHLH treatment.

In eight earlier-stage sHLH patients with lymphoma-associated disease, including six with T cell malignancies, the drug showed a 100% objective tumor response and an 88% complete response rate, including a durable complete response in a patient refractory to more than five prior lines of therapy. Those are genuinely striking numbers. Small n, but striking.

Data Points That Matter

• Cash on hand as of June 30, 2026: $97.7 million in cash, equivalents, and marketable securities.
• Net loss for fiscal 2025: $62.0 million, versus $24.8 million in 2024. Burn is accelerating.
• The company is running a global Phase 2/3 registrational trial in sHLH and expects to complete enrollment in the second half of 2027.
• A second asset, ELA822, is also in development as a monoclonal antibody to selectively deplete activated T cells, with a Phase 1 trial in healthy volunteers initiated in Europe in August 2026.
• No revenue. No pricing terms yet. Pipeline is entirely pre-commercial.

Is the 2026 Window Actually Holding?

This is the real question Electra’s timing forces. The biotech IPO surge has turned 2026 into a comeback year: in the first six months, biopharma companies raised more from initial public offerings than the entire sector managed across all of 2025. By August 23, 21 biotech IPOs had priced in 2026, raising roughly $6.5 billion. Seven of the first 13 U.S. biotechs to list this year added value to their price since going public. That is a majority, but barely.

The Fed backdrop is the wrinkle. July PCE inflation ran at 3.7% year-over-year, with core at 3.3%. The Fed’s target range has been 3.50%-3.75% since December 2025, and CME FedWatch has recently put September hike odds around the coin-flip zone after Warsh’s Jackson Hole remarks. History is not kind to pre-revenue biotech IPOs priced into a tightening cycle. The 2021 cohort, launched into near-zero rates, is the cautionary exhibit: weak aftermarket performance plagued many companies that went public during the boom, and subsequent IPO cohorts often failed to deliver returns.

Bull / Base / Bear

Bull: Breakthrough Therapy designation plus a 100% response rate in a disease with zero approved options is exactly the kind of rare-disease story institutional allocators pay a premium for. An M&A exit before the SURPASS trial reads out is plausible.

Base: The deal prices in a narrow range, trades sideways through enrollment completion in late 2027, and lives or dies on the registrational trial readout. Cash of $97.7 million buys roughly 18 months at the current burn trajectory before a follow-on is needed.

Bear: A September Fed hike compresses multiples across the XBI. Pre-revenue clinical-stage names get re-rated fastest. Electra prices at a discount to get the deal done, and secondary market sellers use any pop to exit.

Action Plan

Do not chase the IPO price. Book-building prices are set for institutional allocators with information advantages and lock-up exits. Your edge as a bargain hunter comes after the lock-up expires, typically 180 days post-listing, when insider selling pressure peaks and the stock often retests or undercuts its IPO price. Watch the SURPASS enrollment pace and any interim safety data as the real catalysts. If a September hike materializes and the XBI pulls back, that is when re-rating creates the entry you actually want.

Cheap Investor Checklist

• Pricing amendment filed with share count and price range: watch for it
• Cash runway relative to SURPASS enrollment completion (targeted second half 2027)
• Post-lock-up price vs. IPO offer price: the real bargain test
• XBI direction in September if the Fed hikes: sector re-rating risk
• Any interim sHLH efficacy or safety signal from SURPASS before year-end
• ELA822 Phase 1 data from the European healthy-volunteer study
• Follow-on offering timeline: with a $62 million annual burn, one is coming

Bottom Line

If the 2026 biotech window survives a September Fed hike, Electra’s rare-disease science and regulatory designations put it among the more credible late-stage filers. If the window cracks, the IPO price is the ceiling, not the floor. Wait for the lock-up, watch the Fed, and let the aftermarket do the price discovery that book-building never will.